Interplay between mycobacteria and host signalling pathways.
Koul
Anil
A
Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, 81377 Munich, Germany. anil.koul@axxima.com
Herget
Thomas
T
Klebl
Bert
B
Ullrich
Axel
A
D000995:Antitubercular Agents / Q000627:therapeutic use; D017209:Apoptosis; D003713:Dendritic Cells / Q000382:microbiology / Q000502:physiology; D006801:Humans; D020935:MAP Kinase Signaling System; D008264:Macrophages / Q000382:microbiology / Q000502:physiology; D008954:Models, Biological; D009161:Mycobacterium / Q000472:pathogenicity* / Q000502:physiology*; D009164:Mycobacterium Infections / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology; D010588:Phagosomes / Q000382:microbiology; D015398:Signal Transduction / Q000502:physiology*; D014376:Tuberculosis / Q000188:drug therapy / Q000382:microbiology / Q000503:physiopathology
D000995:Antitubercular Agents